User profiles for B.A. Cree
 | Bruce CreeProfessor of Neurology, UCSF Verified email at ucsf.edu Cited by 25332 |
Treatment of neuromyelitis optica with rituximab
…, A Miller, T De Angelis, M Matiello, BA Cree - Arch Neurol, 2008 - jamanetwork.com
Background: Neuromyelitis optica (NMO) is an uncommon, life-threatening inflammatory
demyelinating disorder. Recently, much has become known about its immunopathogenesis. …
demyelinating disorder. Recently, much has become known about its immunopathogenesis. …
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
AJ Green, JM Gelfand, BA Cree, C Bevan… - The Lancet, 2017 - thelancet.com
Background Multiple sclerosis is a degenerative inflammatory disease of the CNS characterised
by immune-mediated destruction of myelin and progressive neuroaxonal loss. Myelin in …
by immune-mediated destruction of myelin and progressive neuroaxonal loss. Myelin in …
[HTML][HTML] B cell exchange across the blood-brain barrier in multiple sclerosis
…, L Apeltsin, J Glanville, BA Cree… - The Journal of …, 2012 - Am Soc Clin Investig
In multiple sclerosis (MS) pathogenic B cells likely act on both sides of the blood-brain barrier
(BBB). However, it is unclear whether antigen-experienced B cells are shared between the …
(BBB). However, it is unclear whether antigen-experienced B cells are shared between the …
Progressive multifocal leukoencephalopathy after fingolimod treatment
Objective We describe the characteristics of the 15 patients with fingolimod-associated
progressive multifocal leukoencephalopathy (PML) identified from the Novartis data safety base …
progressive multifocal leukoencephalopathy (PML) identified from the Novartis data safety base …
Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses
… Cree has received personal compensation for consulting from AbbVie, Biogen Idec, EMD
Serono, MedImmune, Novartis, Genzyme/Sanofi Aventis, and Teva Neurosciences. R. Fox has …
Serono, MedImmune, Novartis, Genzyme/Sanofi Aventis, and Teva Neurosciences. R. Fox has …
In vivo evidence of glutamate toxicity in multiple sclerosis
Objective There is increasing evidence that altered glutamate (Glu) homeostasis is involved
in the pathophysiology of multiple sclerosis (MS). The aim of this study was to evaluate the …
in the pathophysiology of multiple sclerosis (MS). The aim of this study was to evaluate the …
Microcystic inner nuclear layer abnormalities and neuromyelitis optica
JM Gelfand, BA Cree, R Nolan, S Arnow… - JAMA …, 2013 - jamanetwork.com
… Dr Cree has received personal compensation for consulting with Biogen-Idec, EMD
Serono, Novartis, Sanofi-Aventis, and Teva Neurosciences. Dr Green has provided consulting …
Serono, Novartis, Sanofi-Aventis, and Teva Neurosciences. Dr Green has provided consulting …
Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis
… Dr Cree has received personal compensation for consulting from Abbvie, Biogen Idec, EMD
Serono, Genzyme/sanofi-aventis, MedImmune, Novartis, and Teva Neurosciences and has …
Serono, Genzyme/sanofi-aventis, MedImmune, Novartis, and Teva Neurosciences and has …
Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures
Background: Health-related quality of life (HRQOL) is reduced in multiple sclerosis (MS). It is
unclear whether HRQOL is associated with white matter lesion burden or measures of brain …
unclear whether HRQOL is associated with white matter lesion burden or measures of brain …
Fulminant demyelinating diseases of the central nervous system
CJ Bevan, BA Cree - Seminars in neurology, 2015 - thieme-connect.com
Fulminant demyelinating diseases of the central nervous system include acute disseminated
encephalomyelitis, the related acute hemorrhagic leukoencephalitis, multiple sclerosis …
encephalomyelitis, the related acute hemorrhagic leukoencephalitis, multiple sclerosis …
